Consolidated Statements of Operations - USD ($) shares in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Net Revenues	$ 486,816,000	$ 316,385,000	$ 216,136,000
Operating Expenses
Cost of sales (excluding depreciation and amortization)	181,513,000	138,785,000	100,610,000
Research and development	34,286,000	22,318,000	11,369,000
Selling, general, and administrative	161,697,000	124,044,000	84,294,000
Depreciation and amortization	59,791,000	56,972,000	47,252,000
Contingent consideration fair value adjustment	1,426,000	3,758,000	500,000
Legal settlement expense	0	0	8,750,000
Purified Cortrophin Gel pre-launch charges	0	0	780,000
Restructuring activities	1,132,000	5,679,000	0
Intangible asset impairment charge	0	112,000	2,374,000
Total Operating Expenses	439,845,000	351,668,000	255,929,000
Operating Income (Loss)	46,971,000	(35,283,000)	(39,793,000)
Other Expense, net
Interest expense, net	(26,940,000)	(28,052,000)	(11,922,000)
Other (expense) income, net	(159,000)	670,000	(4,343,000)
Income (Loss) Before Expense (Benefit) for Income Taxes	19,872,000	(62,665,000)	(56,058,000)
Income tax expense (benefit)	1,093,000	(14,769,000)	(13,455,000)
Net Income (Loss)	18,779,000	(47,896,000)	(42,603,000)
Dividends on Series A Convertible Preferred Stock	(1,625,000)	(1,625,000)	(190,000)
Net Loss Available to Common Shareholders	$ 17,154,000	$ (49,521,000)	$ (42,793,000)
Basic and Diluted Income (Loss) Per Share:
Basic Income (Loss) Per Share (in dollars per share)	$ 0.86	$ (3.05)	$ (3.40)
Diluted Income (Loss) Per Share (in dollars per share)	$ 0.85	$ (3.05)	$ (3.40)
Basic Weighted-Average Shares Outstanding (in shares)	18,001	16,260	12,596
Diluted Weighted-Average Shares Outstanding (in shares)	18,194	16,260	12,596